A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Conditions
Lymphoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
UC San Diego Moores Cancer Center, La Jolla, California, United States
Saddleback Memorial Medical Center, Laguna Hills, California, United States
Hoag Memorial Hospital, Newport Beach, California, United States
University of California Los Angeles (UCLA) - Cancer Care - Santa Monica, Santa Monica, California, United States
Georgetown University, Washington D.C., District of Columbia, United States
AdventHealth Cancer Institute, Orlando, Florida, United States
Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
University of Illinois Cancer Center, Chicago, Illinois, United States
Kansas City VA Medical Center, Kansas City, Kansas, United States
Walter Reed National Military Medical Center, Bethesda, Maryland, United States
Christus Health - Christus St. Vincent Regional Medical Center, Santa Fe, New Mexico, United States
Stony Brook Univ Cancer Ctr, Stony Brook, New York, United States
East Carolina University, Greenville, North Carolina, United States
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
Renovatio Clinical - El Paso, El Paso, Texas, United States
Baylor College of Medicine, Houston, Texas, United States
Renovatio Clinical, The Woodlands, Texas, United States
Auxilio Mutuo Cancer Center, San Juan, Puerto Rico
Study leads
Clinical Trials
Study Director
Hoffmann-La Roche